Intellia Therapeutics Inc (NTLA) concluded trading on Wednesday at a closing price of $11.01, with 4.88 million shares of worth about $53.77 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -56.53% during that period and on January 22, 2025 the price saw a gain of about 10.76%. Currently the company’s common shares owned by public are about 101.80M shares, out of which, 99.79M shares are available for trading.
Stock saw a price change of 13.10% in past 5 days and over the past one month there was a price change of -8.40%. Year-to-date (YTD), NTLA shares are showing a performance of -5.57% which decreased to -56.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.25 but also hit the highest price of $34.87 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 2.93 million. The stock is currently trading -2.00% below its 20-day simple moving average (SMA20), while that difference is down -16.64% for SMA50 and it goes to -45.13% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 101.80M outstanding shares and institutions hold larger chunk of about 92.52% of that.
The stock has a current market capitalization of $1.12B and its 3Y-monthly beta is at 1.79. It has posted earnings per share of -$5.45 in the same period. It has Quick Ratio of 6.73 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 7.40% while standing at 6.18% over the month.
Analysts are in expectations that Intellia Therapeutics Inc (NTLA) stock would likely to be making an EPS of -1.32 in the current quarter, while forecast for next quarter EPS is -1.37 and it is -5.15 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.61 which is -0.88 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.46 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 2.18% while it is estimated to increase by 2.89% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on February 23, 2024 offering a Neutral rating for the stock and assigned a target price range of between $136 and $32 to it. On April 13, 2023, Canaccord Genuity Initiated their recommendations, while on March 21, 2023, Bernstein Initiated their ratings for the stock with a price target of $54. Stock get an Outperform rating from BMO Capital Markets on March 14, 2023.
